文献速递皮肤肿瘤

皮肤肿瘤局部免疫治疗现状与新兴进展

Current and emerging intralesional immunotherapies in cutaneous oncology.
PubMed 文献 · J Am Acad Dermatol · 2024-06-26

皮肤恶性肿瘤的免疫治疗已革新晚期患者管理,但部分患者原发耐药、因合并症不适用或出现限制性全身免疫相关不良事件。为扩大早期患者选择,溶瘤病毒、单克隆抗体、细胞因子、肽类及模式识别受体激动剂等正被开发用于瘤内注射,旨在诱发局部免疫反应并减少全身毒性,临床前及早期临床试验显示良好结果。本综述涵盖瘤内免疫治疗在皮肤黑色素瘤、鳞状细胞癌和基底细胞癌中的应用现状与挑战。

要点

  • 瘤内免疫治疗旨在局部激活抗肿瘤免疫,同时降低全身免疫相关毒性。
  • 涵盖溶瘤病毒、单抗、细胞因子、肽类及模式识别受体激动剂等多元 agents。
  • 适用于皮肤黑色素瘤、鳞状细胞癌和基底细胞癌,尤其早期患者。

核心结论

  • 瘤内免疫治疗是皮肤肿瘤有前景的治疗策略,可在局部诱发免疫反应并减少全身毒性。

研究设计与样本

  • 综述,检索范围未在摘要中明确报告。

主要发现

  • 多种瘤内免疫治疗药物在临床前和早期临床试验中显示出良好结果。

临床怎么用

  • 为晚期免疫治疗原发耐药、因合并症不适用或出现限制性全身免疫相关不良事件的患者提供替代选择。
  • 有望扩展早期皮肤肿瘤患者的治疗选择。

局限性

  • 摘要未报告综述的检索策略、纳入标准及证据质量评价方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunotherapies have revolutionized the management of advanced cutaneous malignancies. However, some patients fail to respond to these therapies, others are ineligible because of comorbidities, and a minority of patients experience treatment-limiting systemic immune-related adverse events. To address these issues and expand treatment options for patients with early-stage disease, a variety of immunotherapies are being developed for direct intratumoral administration. Agents including oncolytic viruses, monoclonal antibodies, cytokines, peptides, and pattern-recognition receptor agonists have been engineered to evoke a local immune response while minimizing systemic toxicity and have shown favorable results in preclinical and early clinical testing. This review covers the current landscape of intratumoral immunotherapies for the treatment of cutaneous melanoma, squamous cell carcinoma, and basal cell carcinoma, highlighting the diverse array of agents being explored and their potential benefits and challenges.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Stull CM, Clark D, Parker T, et al. Current and emerging intralesional immunotherapies in cutaneous oncology. J Am Acad Dermatol. 2024. PMID: 38942173. doi:10.1016/j.jaad.2024.05.095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。